EP1689346A4 - Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants - Google Patents

Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants

Info

Publication number
EP1689346A4
EP1689346A4 EP04811773A EP04811773A EP1689346A4 EP 1689346 A4 EP1689346 A4 EP 1689346A4 EP 04811773 A EP04811773 A EP 04811773A EP 04811773 A EP04811773 A EP 04811773A EP 1689346 A4 EP1689346 A4 EP 1689346A4
Authority
EP
European Patent Office
Prior art keywords
methods
same
monoclonal antibodies
agonistic monoclonal
epha2 agonistic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04811773A
Other languages
German (de)
English (en)
Other versions
EP1689346A2 (fr
Inventor
Michael S Kinch
Kelly Carles-Kinch
Jane C Stewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Purdue Research Foundation
Original Assignee
MedImmune LLC
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC, Purdue Research Foundation filed Critical MedImmune LLC
Publication of EP1689346A2 publication Critical patent/EP1689346A2/fr
Publication of EP1689346A4 publication Critical patent/EP1689346A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP04811773A 2003-11-20 2004-11-19 Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants Withdrawn EP1689346A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52417703P 2003-11-20 2003-11-20
PCT/US2004/039112 WO2005051307A2 (fr) 2003-11-20 2004-11-19 Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants

Publications (2)

Publication Number Publication Date
EP1689346A2 EP1689346A2 (fr) 2006-08-16
EP1689346A4 true EP1689346A4 (fr) 2007-11-21

Family

ID=34632874

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04811773A Withdrawn EP1689346A4 (fr) 2003-11-20 2004-11-19 Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants

Country Status (7)

Country Link
EP (1) EP1689346A4 (fr)
JP (1) JP4860477B2 (fr)
KR (1) KR20060135671A (fr)
CN (1) CN1905899B (fr)
AU (1) AU2004293034B2 (fr)
CA (1) CA2546763A1 (fr)
WO (1) WO2005051307A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
WO2004014292A2 (fr) * 2002-05-10 2004-02-19 Purdue Research Foundation Anticorps monoclonaux agonistes de la epha2 et utilisations de ceux-ci
CA2486615A1 (fr) 2002-05-23 2003-12-04 Purdue Research Foundation Tyrosine phosphatase de faible poids moleculaire (lmw-ptp) servant de cible a usage diagnostique et therapeutique
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
CA2518912A1 (fr) 2003-03-12 2004-09-23 Vasgene Therapeutics, Inc. Composes polypeptidiques permettant d'inhiber l'angiogenese et la croissance tumorale
KR20120123619A (ko) 2004-03-12 2012-11-08 바스진 테라퓨틱스, 인크. 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
AU2005224081B2 (en) 2004-03-12 2011-06-30 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1778726A4 (fr) 2004-08-16 2009-03-18 Medimmune Inc Antagonistes de l'intégrine possédant une action cytotoxique à médiation cellulaire dépendante de l'anticorps améliorée
WO2006034455A2 (fr) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Composes de polypeptides pour l'inhibition de l'angiogenese et de croissance tumorale
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
CA2633718A1 (fr) * 2005-12-21 2007-07-05 Medimmune, Llc Anticorps agonistes d'epha2 a affinites optimisees et methodes d'utilisation de ces anticorps
US20100254996A1 (en) * 2007-06-18 2010-10-07 Medimmune, Llc Synergistic treatment of cells that express epha2 and erbb2
AU2008287427B2 (en) 2007-08-13 2014-10-09 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to EphB4
HRP20170407T1 (hr) * 2007-08-30 2017-05-05 Daiichi Sankyo Company, Limited Anti-epha2 anitijelo
WO2011109440A1 (fr) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarqueurs pour théranostique
WO2011127219A1 (fr) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Biomarqueurs circulants pour une maladie
MX349662B (es) * 2010-07-22 2017-08-08 Univ California Anticuerpos de antigenos antitumorales y metodos de uso.
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
WO2016171242A1 (fr) * 2015-04-24 2016-10-27 第一三共株式会社 Détection d'epha2
CN115025217B (zh) * 2022-05-13 2023-05-05 广东齐美医药生物科技集团有限公司 干细胞裂解物联合活性多糖以及酪氨酸酶抑制剂在制备药物或化妆品中的用途
CN120230214B (zh) * 2025-03-27 2025-09-16 昆明医科大学 一种抗人EphA2的纳米抗体及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012172A1 (fr) * 1999-08-17 2001-02-22 Purdue Research Foundation Traitement de maladies metastatiques
WO2003094859A2 (fr) * 2002-05-10 2003-11-20 Medimmune, Inc. Anticorps monoclonaux contre epha2 et leurs méthodes d'utilisation
WO2004014292A2 (fr) * 2002-05-10 2004-02-19 Purdue Research Foundation Anticorps monoclonaux agonistes de la epha2 et utilisations de ceux-ci
WO2005056766A2 (fr) * 2003-12-04 2005-06-23 Medimmune, Inc. Administration ciblee de medicaments au moyen de groupes fonctionnels liant epha2 ou epha4

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012172A1 (fr) * 1999-08-17 2001-02-22 Purdue Research Foundation Traitement de maladies metastatiques
WO2003094859A2 (fr) * 2002-05-10 2003-11-20 Medimmune, Inc. Anticorps monoclonaux contre epha2 et leurs méthodes d'utilisation
WO2004014292A2 (fr) * 2002-05-10 2004-02-19 Purdue Research Foundation Anticorps monoclonaux agonistes de la epha2 et utilisations de ceux-ci
US20040091486A1 (en) * 2002-05-10 2004-05-13 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
WO2005056766A2 (fr) * 2003-12-04 2005-06-23 Medimmune, Inc. Administration ciblee de medicaments au moyen de groupes fonctionnels liant epha2 ou epha4

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HU MIN ET AL: "Antibody targeting of the EphA2 receptor tyrosine kinase on breast cancer cells.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 44, July 2003 (2003-07-01), & 94TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, DC, USA; JULY 11-14, 2003, pages 1234, XP008079516, ISSN: 0197-016X *
HU MIN ET AL: "EphA2 induction of fibronectin creates a permissive microenvironment for malignant cells.", MOLECULAR CANCER RESEARCH : MCR OCT 2004, vol. 2, no. 10, October 2004 (2004-10-01), pages 533 - 540, XP002435680, ISSN: 1541-7786 *
LANDEN CHARLES N JR ET AL: "Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer", JNCI CANCER SPECTRUM, OXFORD UNIVERSITY PRESS, OXFORD, GB, vol. 98, no. 21, 1 November 2006 (2006-11-01), pages 1558 - 1570, XP002421774, ISSN: 1475-4029 *
MILLER KATHY D ET AL: "EA5, novel EphA2-targeted monoclonal antibody, inhibits growth and metastasis in human breast cancer xenografts.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 46, no. Suppl. S, April 2005 (2005-04-01), & 96TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; ANAHEIM, CA, USA; APRIL 16 -20, 2005, pages 132, XP002435681, ISSN: 0197-016X *

Also Published As

Publication number Publication date
JP2008500021A (ja) 2008-01-10
CN1905899B (zh) 2011-09-28
AU2004293034A1 (en) 2005-06-09
CA2546763A1 (fr) 2005-06-09
WO2005051307A2 (fr) 2005-06-09
CN1905899A (zh) 2007-01-31
WO2005051307A3 (fr) 2006-09-08
KR20060135671A (ko) 2006-12-29
EP1689346A2 (fr) 2006-08-16
AU2004293034B2 (en) 2012-02-02
JP4860477B2 (ja) 2012-01-25

Similar Documents

Publication Publication Date Title
EP1689346A4 (fr) Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants
FR16C1012I2 (fr) Utilisation therapeutique d'anticorps anti-cs1
EP1694301A4 (fr) Procedes et compositions de production d'anticorps monoclonaux
EP1362060A4 (fr) Anticorps monoclonal ds6 et ses procedes d'utilisation
EP1507541A4 (fr) Inhibiteurs et procedes d'utilisation de ceux-ci
EP1572077A4 (fr) Utilisations d'anticorps 8h9 monoclonaux
EP1614693A4 (fr) Purification d'un anticorps monoclonal humain et d'un anticorps polyclonal humain
MA30684B1 (fr) Anticorps anti-mn et leurs procedes d'utilisation.
EP1606285A4 (fr) Inhibiteurs de ido et procedes d'utilisation de ceux-ci
EP1552002A4 (fr) Molecules toxine-aptamere et procedes d'utilisation correspondants
EP1608318A4 (fr) Antagonistes cxcr4 et leurs procedes d'utilisation
EP1831207A4 (fr) Composes d'aminopyrimidine et procedes d'utilisation correspondants
EP1804675A4 (fr) Capteurs combines ameliores, fil-guide et procedes d'utilisation correspondants
PL373333A1 (pl) Stosowanie przeciwciał skierowanych przeciw TNFalfa i innego leku
FR09C0021I2 (fr) Anticorps, compositions, procedes anti-il-12 et leur utilisation
EP1838331A4 (fr) Peptides antimicrobiens et procedes d'utilisation associes
EP1691812A4 (fr) Inhibiteurs de gtpase et procedes d'utilisation correspondants
EP1625140A4 (fr) Composes immunomodulateurs ramifies et leur procedes d'utilisation
EP1487972A4 (fr) Anticorps monoclonaux specifiques de la proteine mn/ca ix generes a partir de souris carentes en mn/ca ix, et methodes d'utilisation
ATE549033T1 (de) Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper
EP1476150A4 (fr) Carboxyfullerenes et procedes d'utilisation de ceux-ci
EP1706791A4 (fr) Compositions de photoresines et leurs procedes d'utilisation
EP1607404A4 (fr) Anticorps monoclonal et hybridome produisant celui-ci
EP1638977A4 (fr) Salinosporamides et leurs methodes d'utilisation
EP1487469A4 (fr) Co-granule de dha et de romarin et procedes d'utilisation associes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060620

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK YU

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/04 20060101ALI20061031BHEP

Ipc: C07K 16/28 20060101ALI20061031BHEP

Ipc: C12P 21/08 20060101ALI20061031BHEP

Ipc: A61K 39/395 20060101AFI20061031BHEP

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/20 20060101ALI20071004BHEP

Ipc: C12N 15/63 20060101ALI20071004BHEP

Ipc: C12N 15/13 20060101ALI20071004BHEP

Ipc: A61P 35/00 20060101ALI20071004BHEP

Ipc: C07H 21/04 20060101ALI20071004BHEP

Ipc: C07K 16/28 20060101ALI20071004BHEP

Ipc: C12P 21/08 20060101ALI20071004BHEP

Ipc: A61K 39/395 20060101AFI20061031BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20071019

17Q First examination report despatched

Effective date: 20080619

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081230